Skip to main content

March 2017, Vol 10, Eighth Annual Payers' Guide

FDA Approvals, FDA Approvals, Drug Updates, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2016

FDA Approvals, FDA Approvals, Drug Updates, Payers' Guide

Welcome to the Eighth Annual Payers’ Guide to New FDA Approvals

Select Drug Profiles, Payers' Guide

Darzalex (Daratumumab) Approved as Part of a 3-Drug Regimen for Patients with Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Defitelio (Defibrotide Sodium): First Drug Approved for Patients with Hepatic Veno-Occlusive Disease

Select Drug Profiles, Payers' Guide

Gazyva (Obinutuzumab) Approved for Patients with Rituximab-Refractory Follicular Lymphoma

Select Drug Profiles, Payers' Guide

Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma

Select Drug Profiles, Payers' Guide

Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Soliqua 100/33 (Insulin Glargine plus Lixisenatide) Receives FDA Approval for Adults with Type 2 Diabetes

1
2

Page 1 of 2
Results 1 - 10 of 14